On a roll, Regeneron and Sanofi boast positive PhIII OS results in 'notoriously' tough cancer
As the sixth checkpoint inhibitor on the US market, Regeneron and Sanofi’s Libtayo has claimed quite a few firsts. And they can now add one …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
